Knight Therapeutics (TSE:GUD) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Knight Therapeutics has reported record revenues for the second quarter of 2024, showcasing a significant increase in both revenue and adjusted EBITDA compared to the previous year. The company credits the growth to its key promoted products and commercial execution in Canada and Latin America, despite a net loss and outflow of cash from operations.
For further insights into TSE:GUD stock, check out TipRanks’ Stock Analysis page.
